Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)

Inhibikase Therapeutics (IKT) has 2 years of Notes Payables data on record, last reported at $248911.0 in Q4 2021.

  • On a quarterly basis, Notes Payables rose 485.2% to $248911.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $248911.0, a 485.2% increase, with the full-year FY2021 number at $248911.0, up 485.2% from a year prior.
  • Notes Payables reached $248911.0 in Q4 2021 per IKT's latest filing, roughly flat from $248911.0 in the prior quarter.
  • Over the last five years, Notes Payables for IKT hit a ceiling of $994789.0 in Q1 2021 and a floor of $42534.0 in Q4 2020.